Literature DB >> 23743987

[ANCA-associated vasculitis].

J U Holle1.   

Abstract

Granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis belong to the anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitides (AAV). They share the feature of vasculitic manifestations in small to medium-size vessel beds which can occur in nearly any organ system. The treatment of AAV is dependent on stage and activity and is carried out on the basis of randomized controlled trials with an initial remission induction regimen followed by maintenance treatment. Apart from glucocorticoids, conventional immunosuppressants are the basis of treatment whereby biologics, such as rituximab have emerged as new treatment options.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743987     DOI: 10.1007/s00393-013-1211-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  26 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients.

Authors:  Pascal Cohen; Christian Pagnoux; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Véronique Le Guern; Marie-Hélène André; Martine Gayraud; David Jayne; Daniel Blöckmans; Jean-François Cordier; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2007-05-15

3.  Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients.

Authors:  Anne Bourgarit; Philippe Le Toumelin; Christian Pagnoux; Pascal Cohen; Alfred Mahr; Véronique Le Guern; Luc Mouthon; Loïc Guillevin
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

4.  Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.

Authors:  L Guillevin; B Durand-Gasselin; R Cevallos; M Gayraud; F Lhote; P Callard; J Amouroux; P Casassus; B Jarrousse
Journal:  Arthritis Rheum       Date:  1999-03

Review 5.  Churg-Strauss syndrome: update on pathophysiology and treatment.

Authors:  Augusto Vaglio; Frank Moosig; Jochen Zwerina
Journal:  Curr Opin Rheumatol       Date:  2012-01       Impact factor: 5.006

6.  Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register.

Authors:  Eva Reinhold-Keller; Karen Herlyn; Rosemarie Wagner-Bastmeyer; Wolfgang L Gross
Journal:  Arthritis Rheum       Date:  2005-02-15

7.  A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients.

Authors:  Frank Moosig; Jan Phillip Bremer; Bernhard Hellmich; Julia Ulrike Holle; Konstanze Holl-Ulrich; Martin Laudien; Christine Matthis; Claudia Metzler; Bernhard Nölle; Gert Richardt; Wolfgang L Gross
Journal:  Ann Rheum Dis       Date:  2012-08-11       Impact factor: 19.103

8.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

9.  Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.

Authors:  Camillo Ribi; Pascal Cohen; Christian Pagnoux; Alfred Mahr; Jean-Pierre Arène; Dominique Lauque; Xavier Puéchal; Philippe Letellier; Philippe Delaval; Jean-François Cordier; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2008-02

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  3 in total

Review 1.  [New drugs in rheumatology].

Authors:  U Müller-Ladner; U Lange
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

2.  [A 58-year-old patient with temporal headache, jaw claudication and B symptoms].

Authors:  M Gehlen; M Schwarz-Eywill; N Schäfer; A Pfeiffer; J Woenkhaus; J H Bräsen
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

3.  [Genetic risk factors for vasculitis].

Authors:  J U Holle; W L Gross
Journal:  Internist (Berl)       Date:  2014-02       Impact factor: 0.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.